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In English
The reforms in 2002 of the Medicines Act and the Sickness
Insurance Act imposed on the National Agency for
Medicines in Finland the responsibility for preparing a list of
medicinal products which are substitutable for one another
since they contain the same amount of the same active sub-
stance, and which are biologically equivalent. In October
2002 NAM formulated the principles for preparing a list of
generically substitutable medicinal products, and published
the first list on its website in February 2003. Generic substi-
tution was subsequently introduced in Finland in April
2003.
The list was initially prepared with the consideration in
mind that substitution could be carried out without
compromising patient safety and without interfering with
treatment compliance or undermining the confidence
among the various parties. The preparation of this list
proved successful. The principles of preparation have
remained almost unchanged for the past three years. The
first list contained 1,502 products with marketing authorisa-
tion, representing 217 active agents or compound groups
and covering about 31% of all medicinal products. The cor-
responding figures in the list established for the first quarter
of 2006 are 3,205 medicinal products, 270 medicinal sub-
stances, and 49% of all medicinal products.
According to our experience at NAM, the principles of
preparation of the list have not been jeopardised, the lists
have been submitted on time, and an additional service has
been offered to the parties concerned, namely, free access to
the database from which the lists can be downloaded. NAM
has ensured that medicinal products of high quality only are
introduced on to the Finnish market: the quality of generi-
cally equivalent products is evaluated using the same criteria
as is applied to the original product, pharmaceutical manu-
facturing is regularly inspected by the authorities, and the
biological equivalence of generic medicinal products is
shown by clinical studies or comparable absorption studies. 
The reform of the Medicines Act in November 2005,
and the three-year experience of generic substitution so far,
have been used as the basis for updating the principles of
preparation of the list and expanding the criteria for substi-
tution.
From the beginning of 2006, the principles of generic
substitution will include the conception that different salts,
esters, ethers, isomers, mixtures of isomers, complexes or
derivatives of an active substance, can under certain condi-
tions, be considered as the same active subtance, and there-
fore be substitutable as long as the rest of the substitution
criteria are fulfilled. In the marketing authorisation applica-
tion procedure, pharmaceutical formulations with immediate
release of the medicinal substance have for years been con-
sidered as  equivalent products (tablets and capsules of vari-
ous forms), and now the same principle is being applied to
generic substitution.
The area of generically substitutable formulations has
been expanded to include prolonged-release tablets and cap-
sules, ointments and shampoos. Prolonged-release tablets
and capsules may be interchangeably substitutable with one
another, in the same way as gastro-resistant tablets and cap-
sules are, as long as the rest of the conditions of equivalence
are fulfilled. Antipsychotics and antidementia drugs are
nowadays also considered generically substitutable. Parallel
distribution referring to parallel imports in the centralised
procedure has been added to the terminology.
Nowadays, doctors, patients, pharmacies and the
pharmaceutical industry are all familiar with their rights and
responsibilities in relation to generic substitution of drugs. A
doctor may as necessary forbid the substitution on medical
or therapeutic grounds. Consideration in the prescribing of
generically substitutable drug products should still be
focused on the patient’s hypersensitivity, difficulties in con-
trolling the level of the disease, compliance with the
treatment, and any errors of medication that may occur. The
patient always has the right, without giving a reason, to
refuse a generic substitute; the refusal will have no effect on
the amount of reimbursement that he or she is entitled to
from the Social Insurance Institution in Finland.
Generic substitution is expanding
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Common sense comes up trumps in the 
withdrawal of benzodiazepines 
Benzodiazepine dependence is charac-
terised by tolerance, i.e. gradually
reduced efficacy, attempts to increase
the dose, withdrawal symptoms as a
result of dose reduction and continua-
tion of use despite the adverse effects.
In practice, there are three
common forms of benzodiazepine
dependence (1). Dependence at usual
therapeutic doses (small dose depend-
ence) is iatrogenic. It occurs in the
elderly or in patients on long-term
therapy after years of use: about half of
the patients in these groups are affect-
ed. In escalating dependence the use
may have started as a common therapy,
which is never discontinued, followed
by gradually increased doses. These
patients may in fact have appoint-
ments with several doctors. In Finland,
2–3% of patients on CNS drugs
belong to the risk group of drug addic-
tion. In the mixed use of intoxicants,
attempts are made to increase the
effects of other intoxicants or to allevi-
ate the withdrawal symptoms with
benzodiazepines.
Harmful use of benzodiazepines is
not characterised by dependence, but
by bodily or mental harm caused by
the use, e.g. behavioural or memory
disturbances. Distinctive findings can
be detected among the withdrawal
symptoms of benzodiazepines (see
Table), and insidiously occasionally
even delirium a couple of weeks later.
The withdrawal symptoms of use
include, in theory, symptoms of recur-
rence (relapse, i.e. the original anxiety
syndrome recurs), and rebound symp-
toms (transient exacerbation of the
original symptoms) as well as the actu-
al withdrawal symptoms (2).
First examine the real nature
of the use 
The actual size of dose and duration of
therapy are established at the start of
the therapy. Data is collected from all
previous situations of treatment. The
patient’s motivation for use and with-
drawal are examined by interview. The
benefits and adverse effects of the
medication are openly discussed with
the patient. Long-term use at least
appears to benefit the patient if the
treatment continues. Some-times no
other treatment is adequate in the con-
trol of symptoms of anxiety or sleep
disturbance, or the medication is clear-
ly beneficial in the treatment of a con-
current psychiatric or neurological ill-
ness of the patient (1, 2, 3).
The harmful effects of long-term
use usually clearly outweigh the bene-
fits (1, 3, 4, 5). Dependence may
develop with any benzodiazepine.
They have a sedative effect and expose
at least a proportion of patients to
accidents. They cause disturbances of
the cognitive function, confusion and
agitation, especially in dementia
patients. They occasionally reduce
impulse control, thereby exposing the
patient to association between the use
of intoxicants and aggressiveness. Ben-
zodiazepines may increase the urge to
drink alcohol in intoxicant users; they
also penetrate the placenta. Overall,
they are harmful in traffic and working
life, which the patient may not always
be aware of. Generally only higher
doses are life-threatening, while, on the
other hand, even minor mixed use
with alcohol can cause unexpected
reactions. Their benefit as sleeping aids
has been proven only in short-term
use. There is no evidence that benzodi-
azepines would be beneficial in the
treatment of alcohol dependency (6).
Withdrawal is associated with sev-
eral benefits. First of all, it is not until
after the withdrawal that a realistic pic-
ture of the need to use the drug is
formed (2). Overall, the patient gets
rid of unnecessary or harmful medica-
tion with subsequent improvement of
life quality. 
An open discussion with the
patient about the diagnostic criteria,
withdrawal symptoms (see Table) and
benefits and adverse effects of the
medication is beneficial. Existing psy-
chiatric disorders are established and
treatment introduced as necessary. In
the presence of symptoms of mood
swings or anxiety disorders, any anti-
If a patient has been on benzodiazepines or short-acting hypnotics for several weeks, critical assessment of the need for med-
ication should be a priority. Total withdrawal is not always the unconditional target, but initiation of the withdrawal
process is recommended if the adverse effects of medication outweigh the benefits. If dependence has developed, sudden
discontinuation of medication is advised against. The use should be tapered out gradually during several weeks, sometimes
even months. It is always preferable that the prescription for benzodiazepines should be issued by one and the same doctor.
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depressant or other medication is rec-
ommended to be introduced at least
2–3 weeks before starting the
withdrawal of benzodiazepines.
Withdrawal is not an uncondition-
al end in itself, because it may also be
harmful. Controlled long-term use
may be possible if the adverse effects of
withdrawal outweigh the benefits
expected. Transient increase in anxiety
and sleep disturbances may occur,
especially if the withdrawal has been
too quick. Withdrawal requires moti-
vation, time, patience and collabo-
ration, also on the part of the doctor
(4, 6). Withdrawal is recommended if
it is expected to improve the condition
of the patient.
Treatment by one physician
At the health centre outpatient clinic
patients are given an appointment with
their own doctor. Prescriptions for
sedatives are not issued as a rule in an
outpatient situation, but acute medica-
tion for withdrawal symptoms is
always prescribed if required (7). Any
symptoms resulting from withdrawal
of intoxicants or medicines are only
treated if objectively found. Threaten-
ing behaviour is not a withdrawal
symptom, and the patient may be
asked to return to the appointment
later, or institutional therapy may be
recommended.
In primary health care, withdrawal
may be started if the dosage is no
higher than about one and a half times
the official recommended maximum
dosage, the patient is not suffering
from a severe psychiatric illness, is not
a user of a mixture of intoxicants and
complies with the treatment plan.
Request for a consultation with a psy-
chiatrist is recommended if collabora-
tion with the patient is poor, or there
are signs of a severe personality disor-
der, or if there is a question of a severe
depression, a severe anxiety disorder or
a history of a psychotic illness. If med-
ication with benzodiazepine is contin-
ued for more than four months with-
out withdrawal, it is recommended
that the opinion of a psychiatrist
should be sought, to ensure that the
diagnosis is correct and to check the
availability of alternative therapies.
A consultation with a psychiatrist
or a doctor specialising in intoxicants,
or a referral to an ’A clinic’ [an outpa-
tient clinic for intoxicant users], is rec-
ommended if previous attempts at
withdrawal have failed, or the initial
daily dose is about one and a half
times the official recommended maxi-
mum dose, or if benzodiazepine med-
ication exceeding the recommended
maximum doses is continued without
attempts at withdrawal; weighing up
the adverse effects and the benefits, for
example, may be the reason for the
consultation. An ’A clinic’ is the
appropriate place for treatment if the
patient is a user of a mixture of intoxi-
cants and a large-scale consumer of
alcohol. Consultation with a neurolo-
gist is recommended if the patient has
a neurological illness the treatment of
which would benefit from benzodiaz-
epines.
It is recommended that withdrawal,
or at least the initiation of it, be
carried out under institutional care,
such as in a health centre in-patient
ward, a social hospital or a psychiatric
ward, if the initial dose of benzo-
diazepine is more than twice the offi-
cial recommended maximum dose
(severe high-dose dependency), the
idea of the initial dose is uncertain, the
patient is dependent on several intoxi-
cants or uses a mixture of them (6),
the patient has other severe illnesses
such as severe sleep apnea, coronary
artery disease, severe depression, or the
patient is using barbiturates.
The treatment management
plan is set out in writing
The management plan for long-term
use or withdrawal is drawn up in writ-
ing. A copy of an entry in a patient
record is adequate if the patient can
sign it. It is important to obtain the
patient’s written permission to collect
the data from previous places of treat-
ment, to obtain permission to forward
immediately to all previous places of
treatment a copy of the management
plan, followed later by information
about its progress, or cancellation,
together with permission to request an
extract from the registers of the local
pharmacies with details of the client’s
medicines purchases over the previous
six months. During treatment the
patient will undergo random testing
consisting of blowing into an alcome-
ter or screening for narcotics. The
patient is advised in advance that any
lost or stolen prescription will not be
replaced; any objectively diagnosed
acute withdrawal symptoms will be
treated as necessary in the emergency
room.
In complicated cases – if the dose
differs from the official dose recom-
mendations, or if the centralisation of
treatment is suspected to be failing, or
if the withdrawal attempts have repeat-
edly failed – an agreement called the
pharmacy agreement will be made.
The patient may be asked to keep a
diary of the use of medicines. The
patient will at the same time identify
any risk situations caused by excessive
use and consider other means of man-
agement (6).
Establishing the initial dose
At first, a daily dose is determined
which will allow the patient a
sufficient amount of sleep and does
not cause withdrawal symptoms such
as tachycardia, hypertension, tremor
and sweating (see Table). Withdrawal
symptoms may also be evaluated by a
scale called CIWA-B.
In institutional care the dose is ini-
tially increased by as much as 20 mg of
diazepam at 2-hourly intervals (up to
200 mg/24 hours), but only if
withdrawal symptoms are perceptible
in the patient’s condition and the
patient is not sedated at all. Very high
initial doses can in most cases be
reduced (in institutional care) by half
within about a week, especially if the
patient is using diazepam. The dose
may be reduced evenly, or in relation
to the severity of the withdrawal symp-
toms; there is no essential difference
between these methods in institutional
care. In severe high-dose dependency
carbamazepine or valproate may be
used as a supportive medication (5). If
a previous attempt at withdrawal has
failed, or the patient is prone to exhib-
it withdrawal symptoms, or the drugs
used are very short-acting, then the
therapy can be replaced, overlapping
with diazepam in accordance with the
equivalent doses over a period of 1–2
weeks.
Withdrawal of low- and high-
dose treatment
If the initial dose exceeds the official
recommended maximum dose, it is
usually possible to reduce the daily
dose by 10–25% at intervals of 1–2
weeks. The recommended maximum
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dose is about 40 mg of diazepam, 120
mg of oxazepam or 6 mg of alprazolam
per day. When the dose is approxi-
mately the recommended maximum,
or below it, the reduction in dose is
carried out carefully by 10–20% at
intervals of 2–3 weeks (1). Sleeping
aids should also be withdrawn gradual-
ly.
Should mild withdrawal symptoms
occur, the dose should not be increased
back to its previous level, but instead a
longer delay should be observed until
the next reduction (2, 4). Withdrawal
symptoms develop within 1–2 days
after the discontinuation of short-act-
ing, and not until within 2–14 days
after the discontinuation of long-act-
ing, benzodiazepines. It is recommend-
ed that any sedatives otherwise usually
taken as required be avoided at this
stage, and regular medication should
be aimed at. The patient is seen at
appointments at monthly intervals,
more frequently at the beginning,
withdrawal symptoms are openly dis-
cussed and the patient is encouraged to
continue the withdrawal (1, 2, 8).
The rate, unlike the target of with-
drawal, may be relaxed as necessary.
The patient will benefit from follow-
up appointments even after comple-
tion of the withdrawal. Relapses are a
risk, and the occurrence of other psy-
chiatric symptoms may require appro-
priate treatment (1, 8). Severe person-
ality disorders undermine the progno-
sis, at least in users of a mixture of
intoxicants.
If withdrawal fails
Should the withdrawal fail, the doctor
should not blame the patient, but
instead, always encourage the patient
to try again. The situation is reported
to other places of treatment in accor-
dance with the treatment management
plan. Supportive medicines are usually
of only little benefit, but they may be
tried, especially if a previous attempt at
withdrawal has failed (1). For example,
propranolol 10–20 mg (40 mg if nec-
essary) administered 2–3 times a day, is
beneficial in the treatment of somatic
excitation symptoms of the autonomic
nervous system. Valproate, carbamaz-
epine and possibly also gabapentin
may somewhat alleviate withdrawal
symptoms or at least improve the out-
come of treatment and inhibit seizures.
Sedative antidepressants (mirtazapine,
mianserin, amitriptyline) alleviate sleep
disturbances (5), similarly to the
administration of 25–100 mg of
hydroxyzine (3). Imipramine supports
the withdrawal in patients with gener-
alised anxiety disorder. The efficacy of
buspirone is inadequate in most cases
in patients dependent on medicines
(4), but positive experiences have also
occurred in patients with generalised
anxiety disorder. Melatonin (a dose of
2–6 mg administered at night) has
occasionally been beneficial for sleep
disturbances at the withdrawal stage.
The use of dexmedetomidine under
the supervision of an anaesthetist has
alleviated the severe withdrawal symp-
toms of benzodiazepines and opioids,
even in the case of a child. It should
always be borne in mind that support-
ive medicines also have their adverse
effects and contraindications.
Drug dependency is
preventable
When introducing benzodiazepines or
other sleep aids, it is recommended
that the point in time at which the
medication will be stopped should be
agreed mutually with the patient (4).
Other alternative therapies should
always be sought for the treatment of
anxiety or sleep disturbances. Natural-
ly, attempts should be made to use the
smallest possible dose. If the drug dose
is small, even a simple recommen-
dation by the doctor to reduce the
medication may work as an encourage-
ment for the patient to reduce the
medication or to have breaks in the
course of treatment.
Benzodiazepine derivatives cause
dependence in various ways. Conse-
quently, in all except acute therapies,
oxazepam or chlorodiazepam would be
preferable (since the effect will not
start too quickly), and the drugs to be
avoided include, for example,
diazepam, lorazepam and alprazolam
(4, 5), at least in patients with depen-
dency. High-dose prescriptions should
be avoided with preference given to
renewals. If the prescription is lost, a
renewal cannot be issued.
The grounds for long-term use
started earlier should be assessed and
determined at least annually (4, 6).
The attitude should not be moralising,
but critical. All except emergency units
could adopt the principle of never pre-
scribing benzodiazepines at first
appointments; this information can
also be made readily available to the
patient.
Withdrawal  symptoms assoc ia ted wi th  benzodiazepines
A f f e c t i v e  s y n d r o m e  a n d  c o g n i t i v e  d i s o r d e r s
Anxiety, fearfulness
Nausea, irritability
Pessimism
Recurring obsessive/compulsive thoughts, mistrustfulness 
S l e e p  d i s o r d e r s
Sleeplessness, disturbed day and night rhythm, daily fatigue
P h y s i c a l  s y m p t o m s  a n d  f i n d i n g s
Tachycardia (pulse over 100/min.), hypertension
Hyperreflexia, muscular tension, tic, tremor, ataxia
Agitation, motor restlessness
Myalgia, arthralgia
Nausea
Sweating
Tinnitus
Grand mal seizures 
P e r c e p t i o n  d i s o r d e r s  
Experiences of depersonalisation (feelings of estrangement)
Loss of visual acuity, improved sense of hearing 
Illusions, hallucinations 
In English
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Hypertension trials have generally
compared a new drug therapy with a
diuretic, to be used as a medication
called ‘current antihypertensive med-
ication’. The drug of comparison has
often been atenolol 50 mg once or
twice daily and bendroflume-thiazide
2.5–5.0 mg per day, corresponding to
25–50 mg of hydrochlorothiazide.
The hypothesis of ASCOT was
that by using a vasodilator therapy,
consisting of amlodipine as necessary
as a combination treatment together
with an ACE inhibitor, perindopril,
the number of non-fatal and fatal car-
diac infarctions would be reduced. The
trial was planned in 1990 and started
in February 1998. The statistical
power of the trial was judged by sug-
gesting that this type of cardiac event
would occur in 2% of the patients in
the beta-blocker group and that the
vasodilator therapy would reduce the
number of cardiac infarctions by 15%
in comparison with the atenolol-
thiazide group. The estimated power of
the trial was 80% with 5% confidence
limits. It was generally recommended
at the planning stage of the trial that
the hypothesis and statistical power of
the trial should be designed so that the
hypothetical model would be superior
to the control group. Consequently,
the non-inferiority principle, i.e.
equivalence of the end points, was not
used in the planning of the statistical
analysis of ASCOT.
In addition to hypertension, at
least three of the following factors
which increase the risk should be pre-
sent in the patients entered in the trial:
smoking, left ventricular hypertrophy,
male sex, coronary artery disease in the
relatives, diabetes, microalbuminuria,
over 55 years of age, history of a cere-
brovascular accident, some other vas-
cular disease, or lipid metabolism dis-
orders. Excluded from the trial were
patients with a history of cardiac
infarction or who were on medication
for symptomatic coronary artery dis-
ease. Patients who had suffered a
stroke during the previous 3 months
were also excluded from the trial.
During the trial, amlodipine was
used for 82% and perindopril for
about 50% of the duration of the
treatment course. At one year into the
trial atenolol was being used by 87%
of the patients and by 79% of the total
duration of the trial. Diuretics were
administered to 66% of the patients.
The third drug administered to some
patients in both groups was alpha-
blocker doxazosine, and in the diuretic
group it was doxazosine and/or
spironolactone.
The trial comprised patients who
had other risk factors, except for symp-
tomatic or otherwise diagnosed coro-
nary artery disease. The drug of com-
parison consisted of a high-dose
thiazide and a beta-blocker. The dose
of atenolol used was that for patients
with symptomatic bradycardia, which
was suffered by 6% of the patients.
The estimated duration of the trial
was around 3.5 years, but since the fre-
quency of cardiac infarctions was
reduced during the trial it was
prolonged to almost six years. 
ASCOT was not interrupted
because of a risk of cardiac infarction,
but on the recommendation of the
safety committee, because, in the first
instance, the number of strokes was
higher in the beta-blocker group, and
finally, because even the total mortality
rate was smaller in the amlodipine
group. The number of cardiac infarc-
tions was not, however, decreased
markedly.
There were 429 primary end points
in the amlodipine group, and 474 in
the atenolol group; while the non-stan-
dardised reduction in risk was 10%
(p< 0.1). The number of events involv-
ing stroke was 23% lower in the
amlodipine group (327/422). The
reduction in numbers of all cardiovas-
cular events and procedures was 16%
with amlodipine therapy. The total
mortality rate was 738 in the amlodip-
ine-perindopril group and 820 in the
atenolol-diuretic group, the reduction
in risk being 11% (p=0.025). New
cases of diabetes emerged clearly more
frequently in the atenolol group, i.e.
799, whereas in the amlodipine group
it was 567; the reduction in risk in the
vasodilator therapy was –30%, p <
0.0001. This is a very important and
noteworthy result, because diabetes is
an important risk factor in cardiovas-
cular diseases.  During the first two
years there were no differences in the
numbers of cardiac infarctions, and
only a small difference emerged in
respect of the vasodilator therapy at a
later follow-up stage.
In relation to treatment practices in
Finland, the result of ASCOT clearly
supports the notion that the primary
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medication in patients who do not suf-
fer from coronary artery disease, car-
diac arrhythmia or hyperkinesia, which
require beta-blocker therapy, could be
vasodilator therapy.
The average age of patients in the
trial was 63 ± 8 years. The conclusions
are therefore not directly applicable to
elderly persons, the recommended
treatment in whom remains a low-dose
diuretic. Neither should the result of
the trial be interpreted in a way that
would exclude the use of a beta-block-
er as an antihypertensive agent. In
response to tachycardia or bradycardia
a beta-blocker therapy may be useful,
and it is very appropriate in combin-
ation therapies.
Previous beta-blocker trials have
been based on high-dose beta-blockers.
In practice, they are nevertheless pre-
scribed according to pulse rate
response in smaller doses than in
extensive treatment trials, and most
patients are also on a vasodilator agent.
It should be noted that a large pro-
portion of patients with hypertension
suffer from cardiac arrhythmia, atrial
fibrillation, tachycardia or palpitations,
and coronary artery complications. As
a rule, the practical arrangements for
individual therapy for hypertension in
Finland are good.
It is clear, however, that beta-block-
er and diuretic therapies, especially
with high doses of atenolol and
thiazide, are associated with an
increased risk of diabetes. This
confirms the main practice prevalent
in Finland for years, i.e. that the daily
dose of hydrochlorothiazide should be
12.5–25 mg.
The statistics of the National
Agency for Medicines in Finland show
that the use of ACE inhibitors and
angiotensin receptor blockers as well as
of calcium channel blockers and beta-
blockers has increased in recent years.
In patients recently diagnosed as hav-
ing hypertension and patients with no
tachycardia or hyperkinesia, and also
in long-term complications of hyper-
tension, the preferred treatment has
consisted of a vasodilator therapy alone
or combined with a low-dose thiazide,
including a beta-blocker later on as
necessary. Consequently, the results of
ASCOT cannot be interpreted as hav-
ing had a significant effect on the
number of serious events in Finland,
but instead, the results are supportive
of the present practice of individual
therapies.
Is there a difference between
the ACE inhibitors and/or
amlodipine?
It is clear that an ACE inhibitor is the
choice more to be recommended in
patients with occasional oedema, espe-
cially if the patient suffers from cardiac
insufficiency. There is no need to
change the calcium channel blocker of
the amlodipine type if the response has
been good and especially if no other
medication is necessary. High doses of
thiazide and/or beta-blockers should
be avoided, because several studies
show that they increase the risk of dia-
betes and stroke. This leads to less
exercise and a weight increase usually
follows.
An evaluation of ASCOT should
take into consideration the patient
material selected and the hypothesis.
In addition, it is important to compare
this with our practice and amend our
recommendations, which are already
making a specific attempt to avoid
high-dose thiazide therapies. A beta-
blocker is probably used as a rule
because of its other effects in hyperten-
sive patients, and the dosage is adjust-
ed individually.
In the treatment of hypertensive
patients it should be borne in mind
that a good control of any additional
risk factors, especially a control of the
cholesterol level with diet and medica-
tion, achieves the biggest reduction in
heart attacks.
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Tamsulosin is a selective antagonist of
α1A-adrenoceptors, the main indica-
tion for which is treatment of
symptoms of benign prostatic hyper-
plasia. The use of tamsulosin in
Finland is fairly extensive (6.6
DDD/1,000 inhabitants/day in 2004
with the defined daily dose of 0.4 mg).
Sufferers from symptoms of prostatic
hyperplasia are often of the same age
group as those who need a cataract
operation.
A recent paper in the Journal of
Cataract and Refractive Surgery has
described a syndrome associated with
the use of tamsulosin and occurring
during cataract surgery; the authors
have named it the IFIS (Intraoperative
Floppy Iris Syndrome) (1). It is a ques-
tion of retrospective data in which 3%
of the cataract patients have been on
tamsulosin therapy. A retrospective
survey has shown that the syndrome
could be found in 10 out of 16 users
of tamsulosin, but in none of those
who had used other systemic α1-
antagonists. One patient with
diagnosed IFIS had not, so far as is
known, used tamsulosin or any other
α1-antagonist. One patient with IFIS
had discontinued the use of tamsulosin
one year, and another patient three
years, prior to the cataract operation.
The authors presumed that the iris
hypotension, which had continued for
so long after discontinuing the medica-
tion, would be a result of diffuse atro-
phy of the dilator pupillae muscle of
the iris, caused by tamsulosin therapy.
Konno and Takayanagi (2) and
Nakamura et al. (2) found that, in rab-
bits, the contraction of the dilator
pupillae muscle of the iris is transmit-
ted via the α1-adrenoceptors. The sub-
type of α1A-adrenoceptors is found to
dominate in the iris, chorioid and reti-
na (4). In vitro studies showed 12–20-
fold tamsulosin affinity with α1A-
adrenoceptors compared with α1B-
receptors, and 2–3-fold compared with
α1D-receptors (5, 6, 7). In a study on
dogs by Sato et al. tamsulosin concen-
tration in plasma was found to de-
crease following oral administration
and to reach the lowest measurable
limit within 4 hours, whereas the con-
centrations in the prostate and the ure-
thra remained at the level of 13–44-
fold (8). This is considered to have
resulted from the long-term binding of
tamsulosin to the target tissues.
During the past few years, male
cataract patients have increasingly been
identified as having an iris with abnor-
mal behaviour during surgery; a floppy
iris which has made surgery more
complicated. Once it emerged that a
common factor in these patients was
tamsulosin therapy, a study with the
aim of explaining the mechanism of
this adverse effect was initiated in
spring 2004 at the Central Hospital of
Keski-Suomi in collaboration with the
University of Kuopio, Department of
Pharmacology. Preliminary results of
the study have recently been published
in the journal Acta Ophthalmol Scand
(9).
By the time of publication of the
study all seven operated patients (and
by today, all of the 17 patients in
total), who had been using tamsulosin,
had been found during surgery to have
IFIS, i.e. a floppy and sail-shaped iris,
while normally the pupil during a
cataract operation is highly dilated and
the iris is very elastic, so that it stays
well in place during surgery and does
not prolapse through the operation
apertures. Six out of seven patients on
tamsulosin therapy were found to have
suffered a prolapsed iris during surgery,
and in four patients the iris tended to
get tangled in the tip of the phaco
equipment used during surgery (9).
Furthermore, the pupil was poorly
dilated and became further significant-
ly contracted in six patients out of
seven in the course of the surgery, thus
complicating the performing of the
operation.
The phenomena described above
complicate cataract operations signifi-
cantly and increase considerably the
risk of other complications associated
with surgery. An iris prolapsed through
the operation apertures may rupture or
become damaged and therefore result
in a deformed pupillary aperture, or
the pupil will no longer contract and
dilate normally. In their patient data,
Chang and Campbell (1) also describ-
ed cases where the posterior capsule of
the lens was ruptured, and loss of vit-
reous body occurred in 12% of their
operations. My own patient data do
not include complications associated
with the posterior capsule.  
In a cataract operation the pupil is
dilated by depressing the pupil
contracting sphincter pupillae muscle
by the use of parasympatholytic drops
(having as the active agent either
cyclopentolate or tropicamide). The
dilation of the pupil is facilitated by
stimulating the sympathomimetically
innervated iris dilator muscle by using
drops of sympathomimetic metaoxed-
rin. It appears that tamsulosin is
strongly bound in the post-synaptic
receptors of the iris dilator muscle and
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thereby inhibits the dilatation of the
pupil. Long-term use of tamsulosin
could result in dilator muscle atrophy,
which would explain the IFIS.
Chang and Campbell (1)
recommended that patients on tamsu-
losin therapy have a break in their
medication for 1–2 weeks prior to
their cataract operation. I have myself
recommended a few patients to have
breaks of variable durations, from 1 to
4 weeks, but even a 4-week break in
medication has not so far removed the
phenomenon; while severe urinary
retention occurred in one patient even
after a one-week break in medication. 
When prescribing tamsulosin, doc-
tors are advised to bear in mind that
the drug causes complications in any
forthcoming cataract operations. In
addition to other drugs, it is also sug-
gested that surgeons pay attention to
the complicating effects of this drug in
particular in surgery. In future, further
explorations are recommended into
how, by modifying the cataract opera-
tion, the above complications caused
by tamsulosin could be further
reduced.
The adverse drug reaction register
of the National Agency for Medicines
in Finland has received three reports of
tamsulosin-induced iris complications
which occurred during cataract
surgery. All of the patients were males
over 70 years of age and on tamsulosin
therapy for benign prostatic hyperpla-
sia. In all of the patients, the cataract
operation had become technically
highly difficult, but permanent dam-
age with adverse effects on the func-
tion of the eye did not develop in any
of them. The adverse effect will be
included in the updates of the SPCs
and PILs of the preparations contain-
ing tamsulosin.
Thus far it is not known whether
this is a class effect.
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